The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

BMC Infect Dis. 2018 Nov 16;18(1):580. doi: 10.1186/s12879-018-3465-2.

Abstract

Background: According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination of sofosbuvir and NS5A inhibitors. Polish national recommendations also allow the use of paritaprevir/ritonavir/ombitasvir+dasasbuvir±ribavirin (PrODR) in this group of patients. The aim of the study was to evaluate the efficacy and safety of PrODR vs. ledipasvir/sofosbuvir±RBV (LSR) in PI-experienced patients in real-life setting.

Methods: Our analysis included patients registered in the nationwide, investigators initiated, multicentre EpiTer-2 database. Among 4530 patients registered, 335 with genotype 1 (93% 1b) were previously treated with IFN-based regimens with PIs: 127 with boceprevir (BOC), 208 with telaprevir (TVR). Patients with advanced fibrosis (F3/F4) were significantly predominant (BOC 28.4%/61.4%, TVR 18.8%/64.4%, respectively). Subjects were assigned to IFN-free retreatment as follows: BOC - 64 (50.4%) PrODR and 63 (49.6%) LSR; TVR- 103 (49.5%) PrODR and 105 (50.5%) LSR.

Results: SVR rates were comparable for particular groups: BOC → PrODR- 100%; BOC → LSR - 98%; TVR → PrODR - 97%; TVR → LSR - 96% (intent-to treat analysis-ITT) and BOC → PrODR→100%; BOC → LSR - 99%; TVR → PrODR - 99%; TVR → LSR - 98% (modified intent-to treat analysis-mITT). Both treatment regimens had a favourable safety profile. Adverse events (AEs) were generally mild or moderate in severity. Three deaths were reported. The treatment was stopped due to AEs in five patients (three treated with PrODR and two with LSR).

Conclusion: Efficacy and safety of treatment with PrODR and LSR is comparable in BOC or TVR-experienced patients.

Keywords: Chronic hepatitis C; Liver cirrhosis; Protease inhibitors; Retreatment; Sustained virologic response.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Anilides / administration & dosage*
  • Anilides / adverse effects
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Benzimidazoles / therapeutic use*
  • Carbamates / administration & dosage*
  • Carbamates / adverse effects
  • Cohort Studies
  • Drug Resistance, Multiple, Viral / drug effects*
  • Drug Therapy, Combination
  • Female
  • Fluorenes / therapeutic use*
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / epidemiology
  • Humans
  • Interferons / administration & dosage
  • Interferons / adverse effects
  • Macrocyclic Compounds / administration & dosage*
  • Macrocyclic Compounds / adverse effects
  • Male
  • Middle Aged
  • Poland / epidemiology
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / adverse effects
  • Ritonavir / administration & dosage*
  • Ritonavir / adverse effects
  • Sofosbuvir
  • Sulfonamides / administration & dosage*
  • Sulfonamides / adverse effects
  • Treatment Outcome
  • Uracil / administration & dosage
  • Uracil / adverse effects
  • Uracil / analogs & derivatives*
  • Uridine Monophosphate / analogs & derivatives*
  • Uridine Monophosphate / therapeutic use
  • Young Adult

Substances

  • ABT-267
  • ABT-333
  • Anilides
  • Antiviral Agents
  • Benzimidazoles
  • Carbamates
  • Fluorenes
  • Macrocyclic Compounds
  • Protease Inhibitors
  • Sulfonamides
  • ledipasvir, sofosbuvir drug combination
  • Uracil
  • Interferons
  • Uridine Monophosphate
  • Ritonavir
  • paritaprevir
  • Sofosbuvir